Nanobiotix Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Nanobiotix kazanç ve gelirinin sırasıyla yıllık 16.2% ve 7.7% oranında artması tahmin edilirken, EPS'nin yıllık 21.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

16.2%

Kazanç büyüme oranı

21.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	37.3%
Gelir büyüme oranı	7.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0QAV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	47	-19	51	-5	4
12/31/2025	32	-44	-43	-47	5
12/31/2024	17	-51	-49	-41	5
6/30/2024	42	-33	-2	-1	N/A
3/31/2024	39	-37	-7	-7	N/A
12/31/2023	36	-40	-13	-12	N/A
9/30/2023	21	-49	-25	-25	N/A
6/30/2023	7	-59	-37	-37	N/A
3/31/2023	6	-58	-37	-37	N/A
12/31/2022	5	-57	-37	-37	N/A
9/30/2022	4	-50	-35	-35	N/A
6/30/2022	3	-43	-33	-32	N/A
3/31/2022	3	-45	-31	-31	N/A
12/31/2021	3	-47	-30	-30	N/A
9/30/2021	2	-45	-30	-30	N/A
6/30/2021	2	-43	-30	-30	N/A
3/31/2021	2	-39	-29	-29	N/A
12/31/2020	2	-34	-28	-28	N/A
9/30/2020	2	-41	-31	-30	N/A
6/30/2020	2	-48	-33	-33	N/A
3/31/2020	2	-49	-38	-37	N/A
12/31/2019	3	-51	-43	-41	N/A
9/30/2019	3	-46	-38	-37	N/A
6/30/2019	3	-42	-34	-33	N/A
3/31/2019	3	-36	-30	-30	N/A
12/31/2018	3	-30	-26	-26	N/A
9/30/2018	4	-28	-25	-24	N/A
6/30/2018	4	-27	-24	-22	N/A
3/31/2018	4	-26	N/A	-22	N/A
12/31/2017	4	-26	N/A	-21	N/A
9/30/2017	4	-25	N/A	-20	N/A
6/30/2017	4	-24	N/A	-19	N/A
3/31/2017	5	-23	N/A	-19	N/A
12/31/2016	5	-22	N/A	-18	N/A
9/30/2016	5	-21	N/A	-19	N/A
6/30/2016	5	-19	N/A	-20	N/A
3/31/2016	5	-18	N/A	-19	N/A
12/31/2015	4	-17	N/A	-17	N/A
9/30/2015	4	-15	N/A	-15	N/A
6/30/2015	3	-13	N/A	-12	N/A
3/31/2015	3	-11	N/A	-11	N/A
12/31/2014	3	-10	N/A	-9	N/A
9/30/2014	2	-9	N/A	-8	N/A
6/30/2014	2	-8	N/A	-8	N/A
3/31/2014	2	-8	N/A	-7	N/A
12/31/2013	2	-8	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0QAV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0QAV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0QAV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0QAV şirketinin gelirinin (yıllık 7.7% ) UK pazarından (yıllık 3.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0QAV şirketinin gelirinin (yıllık 7.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0QAV 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Nanobiotix Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

First half 2024 earnings released: €0.46 loss per share (vs €0.80 loss in 1H 2023)

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

New minor risk - Financial position

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Forecast to breakeven in 2024

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Full year 2021 earnings released: €1.35 loss per share (vs €1.38 loss in FY 2020)

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.00

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

New 90-day high: €13.86

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces Positive New Pre-Clinical Data Suggesting Radioenhancer NBTXR3 Could Have A Significant Impact in Immunotherapy

Nanobiotix Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

New 90-day low: €6.05

Nanobiotix Provides Updates on Global Clinical Development Plan for First-In-Class Radioenhancer Nbtxr3 At Astro 2020

NANOBIOTIX Announces First Patient Injected with Nbtxr3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials from U.S. FDA

New 90-day low: €6.25

First half earnings released

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €20.13 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin